Disc Medicine, Inc. (NASDAQ: IRON) Stock Competitors & Peer Comparison
See IRON's competitors and their performance on the NASDAQ and across the wider stock market.
Peer Comparison Table: Biotechnology Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for IRON and its NASDAQ peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| IRON | $74.12 | -2.29% | 2.8B | -11.20 | -$6.62 | N/A |
| VRTX | $477.36 | +0.90% | 121.1B | 25.36 | $18.82 | N/A |
| VRNA | $106.91 | +0.11% | 72.7B | -102.80 | -$1.04 | N/A |
| REGN | $656.01 | +0.63% | 67.6B | 14.38 | $45.63 | +0.55% |
| ARGX | $918.22 | -0.69% | 57.1B | 82.87 | $11.08 | N/A |
| SGEN | $228.74 | -0.07% | 43.2B | -57.19 | -$4.00 | N/A |
| RVMDW | $9.50 | -0.31% | 41.8B | -2.29 | -$4.15 | N/A |
| RVMD | $189.23 | +0.25% | 40.2B | -26.77 | -$7.07 | N/A |
| ALNY | $271.77 | +1.13% | 36.3B | 48.97 | $5.55 | N/A |
| ONC | $325.90 | -0.27% | 34.8B | 72.91 | $4.47 | N/A |
Stock Comparison
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX)
IRON vs VRTX Comparison July 2026
Disc Medicine, Inc. (NASDAQ: IRON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IRON stands at 2.8B. In comparison, VRTX has a market cap of 121.1B. Regarding current trading prices, IRON is priced at $74.12 on the NASDAQ, while VRTX trades at $477.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IRON currently has a P/E ratio of -11.20, whereas VRTX's P/E ratio is 25.36. In terms of profitability, IRON's ROE is -0.37%, compared to VRTX's ROE of +0.24%. Regarding short-term risk, IRON is more volatile compared to VRTX. This indicates higher risk in terms of short-term price fluctuations for IRON.Check VRTX's competition here
Verona Pharma plc (NASDAQ: VRNA)
IRON vs VRNA Comparison July 2026
Disc Medicine, Inc. (NASDAQ: IRON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IRON stands at 2.8B. In comparison, VRNA has a market cap of 72.7B. Regarding current trading prices, IRON is priced at $74.12 on the NASDAQ, while VRNA trades at $106.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IRON currently has a P/E ratio of -11.20, whereas VRNA's P/E ratio is -102.80. In terms of profitability, IRON's ROE is -0.37%, compared to VRNA's ROE of -0.02%. Regarding short-term risk, IRON is more volatile compared to VRNA. This indicates higher risk in terms of short-term price fluctuations for IRON.Check VRNA's competition here
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN)
IRON vs REGN Comparison July 2026
Disc Medicine, Inc. (NASDAQ: IRON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IRON stands at 2.8B. In comparison, REGN has a market cap of 67.6B. Regarding current trading prices, IRON is priced at $74.12 on the NASDAQ, while REGN trades at $656.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IRON currently has a P/E ratio of -11.20, whereas REGN's P/E ratio is 14.38. In terms of profitability, IRON's ROE is -0.37%, compared to REGN's ROE of +0.14%. Regarding short-term risk, IRON is more volatile compared to REGN. This indicates higher risk in terms of short-term price fluctuations for IRON.Check REGN's competition here
argenx SE (NASDAQ: ARGX)
IRON vs ARGX Comparison July 2026
Disc Medicine, Inc. (NASDAQ: IRON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IRON stands at 2.8B. In comparison, ARGX has a market cap of 57.1B. Regarding current trading prices, IRON is priced at $74.12 on the NASDAQ, while ARGX trades at $918.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IRON currently has a P/E ratio of -11.20, whereas ARGX's P/E ratio is 82.87. In terms of profitability, IRON's ROE is -0.37%, compared to ARGX's ROE of +0.22%. Regarding short-term risk, IRON is more volatile compared to ARGX. This indicates higher risk in terms of short-term price fluctuations for IRON.Check ARGX's competition here
Seagen Inc. (NASDAQ: SGEN)
IRON vs SGEN Comparison July 2026
Disc Medicine, Inc. (NASDAQ: IRON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IRON stands at 2.8B. In comparison, SGEN has a market cap of 43.2B. Regarding current trading prices, IRON is priced at $74.12 on the NASDAQ, while SGEN trades at $228.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IRON currently has a P/E ratio of -11.20, whereas SGEN's P/E ratio is -57.19. In terms of profitability, IRON's ROE is -0.37%, compared to SGEN's ROE of -0.21%. Regarding short-term risk, IRON is more volatile compared to SGEN. This indicates higher risk in terms of short-term price fluctuations for IRON.Check SGEN's competition here
Revolution Medicines, Inc. Warrant (NASDAQ: RVMDW)
IRON vs RVMDW Comparison July 2026
Disc Medicine, Inc. (NASDAQ: IRON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IRON stands at 2.8B. In comparison, RVMDW has a market cap of 41.8B. Regarding current trading prices, IRON is priced at $74.12 on the NASDAQ, while RVMDW trades at $9.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IRON currently has a P/E ratio of -11.20, whereas RVMDW's P/E ratio is -2.29. In terms of profitability, IRON's ROE is -0.37%, compared to RVMDW's ROE of -0.83%. Regarding short-term risk, IRON is less volatile compared to RVMDW. This indicates lower risk in terms of short-term price fluctuations for IRON.Check RVMDW's competition here
Revolution Medicines, Inc. (NASDAQ: RVMD)
IRON vs RVMD Comparison July 2026
Disc Medicine, Inc. (NASDAQ: IRON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IRON stands at 2.8B. In comparison, RVMD has a market cap of 40.2B. Regarding current trading prices, IRON is priced at $74.12 on the NASDAQ, while RVMD trades at $189.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IRON currently has a P/E ratio of -11.20, whereas RVMD's P/E ratio is -26.77. In terms of profitability, IRON's ROE is -0.37%, compared to RVMD's ROE of -0.83%. Regarding short-term risk, IRON is more volatile compared to RVMD. This indicates higher risk in terms of short-term price fluctuations for IRON.Check RVMD's competition here
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY)
IRON vs ALNY Comparison July 2026
Disc Medicine, Inc. (NASDAQ: IRON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IRON stands at 2.8B. In comparison, ALNY has a market cap of 36.3B. Regarding current trading prices, IRON is priced at $74.12 on the NASDAQ, while ALNY trades at $271.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IRON currently has a P/E ratio of -11.20, whereas ALNY's P/E ratio is 48.97. In terms of profitability, IRON's ROE is -0.37%, compared to ALNY's ROE of +0.98%. Regarding short-term risk, IRON is more volatile compared to ALNY. This indicates higher risk in terms of short-term price fluctuations for IRON.Check ALNY's competition here
BeOne Medicines AG (NASDAQ: ONC)
IRON vs ONC Comparison July 2026
Disc Medicine, Inc. (NASDAQ: IRON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IRON stands at 2.8B. In comparison, ONC has a market cap of 34.8B. Regarding current trading prices, IRON is priced at $74.12 on the NASDAQ, while ONC trades at $325.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IRON currently has a P/E ratio of -11.20, whereas ONC's P/E ratio is 72.91. In terms of profitability, IRON's ROE is -0.37%, compared to ONC's ROE of +0.12%. Regarding short-term risk, IRON is more volatile compared to ONC. This indicates higher risk in terms of short-term price fluctuations for IRON.Check ONC's competition here
Roivant Sciences Ltd. (NASDAQ: ROIV)
IRON vs ROIV Comparison July 2026
Disc Medicine, Inc. (NASDAQ: IRON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IRON stands at 2.8B. In comparison, ROIV has a market cap of 25.2B. Regarding current trading prices, IRON is priced at $74.12 on the NASDAQ, while ROIV trades at $35.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IRON currently has a P/E ratio of -11.20, whereas ROIV's P/E ratio is -35.99. In terms of profitability, IRON's ROE is -0.37%, compared to ROIV's ROE of -0.07%. Regarding short-term risk, IRON is more volatile compared to ROIV. This indicates higher risk in terms of short-term price fluctuations for IRON.Check ROIV's competition here
Incyte Corporation (NASDAQ: INCY)
IRON vs INCY Comparison July 2026
Disc Medicine, Inc. (NASDAQ: IRON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IRON stands at 2.8B. In comparison, INCY has a market cap of 23.5B. Regarding current trading prices, IRON is priced at $74.12 on the NASDAQ, while INCY trades at $117.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IRON currently has a P/E ratio of -11.20, whereas INCY's P/E ratio is 15.82. In terms of profitability, IRON's ROE is -0.37%, compared to INCY's ROE of +0.29%. Regarding short-term risk, IRON is more volatile compared to INCY. This indicates higher risk in terms of short-term price fluctuations for IRON.Check INCY's competition here
Insmed Incorporated (NASDAQ: INSM)
IRON vs INSM Comparison July 2026
Disc Medicine, Inc. (NASDAQ: IRON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IRON stands at 2.8B. In comparison, INSM has a market cap of 23.2B. Regarding current trading prices, IRON is priced at $74.12 on the NASDAQ, while INSM trades at $106.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IRON currently has a P/E ratio of -11.20, whereas INSM's P/E ratio is -18.59. In terms of profitability, IRON's ROE is -0.37%, compared to INSM's ROE of -1.30%. Regarding short-term risk, IRON is more volatile compared to INSM. This indicates higher risk in terms of short-term price fluctuations for IRON.Check INSM's competition here
BioNTech SE (NASDAQ: BNTX)
IRON vs BNTX Comparison July 2026
Disc Medicine, Inc. (NASDAQ: IRON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IRON stands at 2.8B. In comparison, BNTX has a market cap of 22.6B. Regarding current trading prices, IRON is priced at $74.12 on the NASDAQ, while BNTX trades at $89.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IRON currently has a P/E ratio of -11.20, whereas BNTX's P/E ratio is -19.34. In terms of profitability, IRON's ROE is -0.37%, compared to BNTX's ROE of -0.07%. Regarding short-term risk, IRON is more volatile compared to BNTX. This indicates higher risk in terms of short-term price fluctuations for IRON.Check BNTX's competition here
United Therapeutics Corporation (NASDAQ: UTHR)
IRON vs UTHR Comparison July 2026
Disc Medicine, Inc. (NASDAQ: IRON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IRON stands at 2.8B. In comparison, UTHR has a market cap of 22.4B. Regarding current trading prices, IRON is priced at $74.12 on the NASDAQ, while UTHR trades at $528.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IRON currently has a P/E ratio of -11.20, whereas UTHR's P/E ratio is 19.51. In terms of profitability, IRON's ROE is -0.37%, compared to UTHR's ROE of +0.19%. Regarding short-term risk, IRON is more volatile compared to UTHR. This indicates higher risk in terms of short-term price fluctuations for IRON.Check UTHR's competition here
Moderna, Inc. (NASDAQ: MRNA)
IRON vs MRNA Comparison July 2026
Disc Medicine, Inc. (NASDAQ: IRON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IRON stands at 2.8B. In comparison, MRNA has a market cap of 21.4B. Regarding current trading prices, IRON is priced at $74.12 on the NASDAQ, while MRNA trades at $54.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IRON currently has a P/E ratio of -11.20, whereas MRNA's P/E ratio is -6.63. In terms of profitability, IRON's ROE is -0.37%, compared to MRNA's ROE of -0.37%. Regarding short-term risk, IRON is less volatile compared to MRNA. This indicates lower risk in terms of short-term price fluctuations for IRON.Check MRNA's competition here
BeiGene, Ltd. (NASDAQ: BGNE)
IRON vs BGNE Comparison July 2026
Disc Medicine, Inc. (NASDAQ: IRON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IRON stands at 2.8B. In comparison, BGNE has a market cap of 20.2B. Regarding current trading prices, IRON is priced at $74.12 on the NASDAQ, while BGNE trades at $184.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IRON currently has a P/E ratio of -11.20, whereas BGNE's P/E ratio is -22.55. In terms of profitability, IRON's ROE is -0.37%, compared to BGNE's ROE of +0.12%. Regarding short-term risk, IRON is more volatile compared to BGNE. This indicates higher risk in terms of short-term price fluctuations for IRON.Check BGNE's competition here
Ginkgo Bioworks Holdings, Inc. WT (NYSE: DNA-WT)
IRON vs DNA-WT Comparison July 2026
Disc Medicine, Inc. (NASDAQ: IRON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IRON stands at 2.8B. In comparison, DNA-WT has a market cap of 18.7B. Regarding current trading prices, IRON is priced at $74.12 on the NASDAQ, while DNA-WT trades at $0.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IRON currently has a P/E ratio of -11.20, whereas DNA-WT's P/E ratio is N/A. In terms of profitability, IRON's ROE is -0.37%, compared to DNA-WT's ROE of -0.57%. Regarding short-term risk, IRON is less volatile compared to DNA-WT. This indicates lower risk in terms of short-term price fluctuations for IRON.Check DNA-WT's competition here
Genmab A/S (NASDAQ: GMAB)
IRON vs GMAB Comparison July 2026
Disc Medicine, Inc. (NASDAQ: IRON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IRON stands at 2.8B. In comparison, GMAB has a market cap of 17.7B. Regarding current trading prices, IRON is priced at $74.12 on the NASDAQ, while GMAB trades at $28.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IRON currently has a P/E ratio of -11.20, whereas GMAB's P/E ratio is 20.77. In terms of profitability, IRON's ROE is -0.37%, compared to GMAB's ROE of +0.15%. Regarding short-term risk, IRON is more volatile compared to GMAB. This indicates higher risk in terms of short-term price fluctuations for IRON.Check GMAB's competition here
Neurocrine Biosciences, Inc. (NASDAQ: NBIX)
IRON vs NBIX Comparison July 2026
Disc Medicine, Inc. (NASDAQ: IRON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IRON stands at 2.8B. In comparison, NBIX has a market cap of 17.7B. Regarding current trading prices, IRON is priced at $74.12 on the NASDAQ, while NBIX trades at $175.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IRON currently has a P/E ratio of -11.20, whereas NBIX's P/E ratio is 25.40. In terms of profitability, IRON's ROE is -0.37%, compared to NBIX's ROE of +0.22%. Regarding short-term risk, IRON is more volatile compared to NBIX. This indicates higher risk in terms of short-term price fluctuations for IRON.Check NBIX's competition here
BridgeBio Pharma, Inc. (NASDAQ: BBIO)
IRON vs BBIO Comparison July 2026
Disc Medicine, Inc. (NASDAQ: IRON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IRON stands at 2.8B. In comparison, BBIO has a market cap of 16.5B. Regarding current trading prices, IRON is priced at $74.12 on the NASDAQ, while BBIO trades at $84.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IRON currently has a P/E ratio of -11.20, whereas BBIO's P/E ratio is -22.47. In terms of profitability, IRON's ROE is -0.37%, compared to BBIO's ROE of +0.36%. Regarding short-term risk, IRON is more volatile compared to BBIO. This indicates higher risk in terms of short-term price fluctuations for IRON.Check BBIO's competition here
Jazz Pharmaceuticals plc (NASDAQ: JAZZ)
IRON vs JAZZ Comparison July 2026
Disc Medicine, Inc. (NASDAQ: IRON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IRON stands at 2.8B. In comparison, JAZZ has a market cap of 15.9B. Regarding current trading prices, IRON is priced at $74.12 on the NASDAQ, while JAZZ trades at $253.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IRON currently has a P/E ratio of -11.20, whereas JAZZ's P/E ratio is 19.74. In terms of profitability, IRON's ROE is -0.37%, compared to JAZZ's ROE of +0.01%. Regarding short-term risk, IRON is more volatile compared to JAZZ. This indicates higher risk in terms of short-term price fluctuations for IRON.Check JAZZ's competition here
Ascendis Pharma A/S (NASDAQ: ASND)
IRON vs ASND Comparison July 2026
Disc Medicine, Inc. (NASDAQ: IRON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IRON stands at 2.8B. In comparison, ASND has a market cap of 15.8B. Regarding current trading prices, IRON is priced at $74.12 on the NASDAQ, while ASND trades at $253.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IRON currently has a P/E ratio of -11.20, whereas ASND's P/E ratio is -104.90. In terms of profitability, IRON's ROE is -0.37%, compared to ASND's ROE of -56.42%. Regarding short-term risk, IRON is more volatile compared to ASND. This indicates higher risk in terms of short-term price fluctuations for IRON.Check ASND's competition here
Exelixis, Inc. (NASDAQ: EXEL)
IRON vs EXEL Comparison July 2026
Disc Medicine, Inc. (NASDAQ: IRON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IRON stands at 2.8B. In comparison, EXEL has a market cap of 13.9B. Regarding current trading prices, IRON is priced at $74.12 on the NASDAQ, while EXEL trades at $55.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IRON currently has a P/E ratio of -11.20, whereas EXEL's P/E ratio is 16.58. In terms of profitability, IRON's ROE is -0.37%, compared to EXEL's ROE of +0.40%. Regarding short-term risk, IRON is more volatile compared to EXEL. This indicates higher risk in terms of short-term price fluctuations for IRON.Check EXEL's competition here
Karuna Therapeutics, Inc. (NASDAQ: KRTX)
IRON vs KRTX Comparison July 2026
Disc Medicine, Inc. (NASDAQ: IRON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IRON stands at 2.8B. In comparison, KRTX has a market cap of 12.6B. Regarding current trading prices, IRON is priced at $74.12 on the NASDAQ, while KRTX trades at $329.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IRON currently has a P/E ratio of -11.20, whereas KRTX's P/E ratio is -28.09. In terms of profitability, IRON's ROE is -0.37%, compared to KRTX's ROE of -0.36%. Regarding short-term risk, IRON is more volatile compared to KRTX. This indicates higher risk in terms of short-term price fluctuations for IRON.Check KRTX's competition here
Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL)
IRON vs MDGL Comparison July 2026
Disc Medicine, Inc. (NASDAQ: IRON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IRON stands at 2.8B. In comparison, MDGL has a market cap of 12.6B. Regarding current trading prices, IRON is priced at $74.12 on the NASDAQ, while MDGL trades at $544.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IRON currently has a P/E ratio of -11.20, whereas MDGL's P/E ratio is -42.54. In terms of profitability, IRON's ROE is -0.37%, compared to MDGL's ROE of -0.50%. Regarding short-term risk, IRON is more volatile compared to MDGL. This indicates higher risk in terms of short-term price fluctuations for IRON.Check MDGL's competition here
Axsome Therapeutics, Inc. (NASDAQ: AXSM)
IRON vs AXSM Comparison July 2026
Disc Medicine, Inc. (NASDAQ: IRON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IRON stands at 2.8B. In comparison, AXSM has a market cap of 12.4B. Regarding current trading prices, IRON is priced at $74.12 on the NASDAQ, while AXSM trades at $241.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IRON currently has a P/E ratio of -11.20, whereas AXSM's P/E ratio is -62.92. In terms of profitability, IRON's ROE is -0.37%, compared to AXSM's ROE of -2.60%. Regarding short-term risk, IRON is more volatile compared to AXSM. This indicates higher risk in terms of short-term price fluctuations for IRON.Check AXSM's competition here
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR)
IRON vs ARWR Comparison July 2026
Disc Medicine, Inc. (NASDAQ: IRON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IRON stands at 2.8B. In comparison, ARWR has a market cap of 12.1B. Regarding current trading prices, IRON is priced at $74.12 on the NASDAQ, while ARWR trades at $85.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IRON currently has a P/E ratio of -11.20, whereas ARWR's P/E ratio is -39.81. In terms of profitability, IRON's ROE is -0.37%, compared to ARWR's ROE of -0.55%. Regarding short-term risk, IRON is more volatile compared to ARWR. This indicates higher risk in terms of short-term price fluctuations for IRON.Check ARWR's competition here
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN)
IRON vs BMRN Comparison July 2026
Disc Medicine, Inc. (NASDAQ: IRON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IRON stands at 2.8B. In comparison, BMRN has a market cap of 11.5B. Regarding current trading prices, IRON is priced at $74.12 on the NASDAQ, while BMRN trades at $59.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IRON currently has a P/E ratio of -11.20, whereas BMRN's P/E ratio is 28.52. In terms of profitability, IRON's ROE is -0.37%, compared to BMRN's ROE of +0.04%. Regarding short-term risk, IRON is more volatile compared to BMRN. This indicates higher risk in terms of short-term price fluctuations for IRON.Check BMRN's competition here
Avidity Biosciences Inc (NASDAQ: RNAM)
IRON vs RNAM Comparison July 2026
Disc Medicine, Inc. (NASDAQ: IRON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IRON stands at 2.8B. In comparison, RNAM has a market cap of 11.3B. Regarding current trading prices, IRON is priced at $74.12 on the NASDAQ, while RNAM trades at $72.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IRON currently has a P/E ratio of -11.20, whereas RNAM's P/E ratio is -17.39. In terms of profitability, IRON's ROE is -0.37%, compared to RNAM's ROE of -0.45%. Regarding short-term risk, IRON is more volatile compared to RNAM. This indicates higher risk in terms of short-term price fluctuations for IRON.Check RNAM's competition here
Bio-Techne Corporation (NASDAQ: TECH)
IRON vs TECH Comparison July 2026
Disc Medicine, Inc. (NASDAQ: IRON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IRON stands at 2.8B. In comparison, TECH has a market cap of 11.2B. Regarding current trading prices, IRON is priced at $74.12 on the NASDAQ, while TECH trades at $71.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IRON currently has a P/E ratio of -11.20, whereas TECH's P/E ratio is 36.91. In terms of profitability, IRON's ROE is -0.37%, compared to TECH's ROE of +0.05%. Regarding short-term risk, IRON is more volatile compared to TECH. This indicates higher risk in terms of short-term price fluctuations for IRON.Check TECH's competition here
Summit Therapeutics Inc. (NASDAQ: SMMT)
IRON vs SMMT Comparison July 2026
Disc Medicine, Inc. (NASDAQ: IRON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IRON stands at 2.8B. In comparison, SMMT has a market cap of 10.6B. Regarding current trading prices, IRON is priced at $74.12 on the NASDAQ, while SMMT trades at $13.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IRON currently has a P/E ratio of -11.20, whereas SMMT's P/E ratio is -8.54. In terms of profitability, IRON's ROE is -0.37%, compared to SMMT's ROE of -2.04%. Regarding short-term risk, IRON is less volatile compared to SMMT. This indicates lower risk in terms of short-term price fluctuations for IRON.Check SMMT's competition here
Cytokinetics, Incorporated (NASDAQ: CYTK)
IRON vs CYTK Comparison July 2026
Disc Medicine, Inc. (NASDAQ: IRON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IRON stands at 2.8B. In comparison, CYTK has a market cap of 10B. Regarding current trading prices, IRON is priced at $74.12 on the NASDAQ, while CYTK trades at $80.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IRON currently has a P/E ratio of -11.20, whereas CYTK's P/E ratio is -13.85. In terms of profitability, IRON's ROE is -0.37%, compared to CYTK's ROE of +1.40%. Regarding short-term risk, IRON is more volatile compared to CYTK. This indicates higher risk in terms of short-term price fluctuations for IRON.Check CYTK's competition here
Krystal Biotech, Inc. (NASDAQ: KRYS)
IRON vs KRYS Comparison July 2026
Disc Medicine, Inc. (NASDAQ: IRON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IRON stands at 2.8B. In comparison, KRYS has a market cap of 9.9B. Regarding current trading prices, IRON is priced at $74.12 on the NASDAQ, while KRYS trades at $335.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IRON currently has a P/E ratio of -11.20, whereas KRYS's P/E ratio is 44.81. In terms of profitability, IRON's ROE is -0.37%, compared to KRYS's ROE of +0.19%. Regarding short-term risk, IRON is more volatile compared to KRYS. This indicates higher risk in terms of short-term price fluctuations for IRON.Check KRYS's competition here
Halozyme Therapeutics, Inc. (NASDAQ: HALO)
IRON vs HALO Comparison July 2026
Disc Medicine, Inc. (NASDAQ: IRON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IRON stands at 2.8B. In comparison, HALO has a market cap of 9.7B. Regarding current trading prices, IRON is priced at $74.12 on the NASDAQ, while HALO trades at $81.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IRON currently has a P/E ratio of -11.20, whereas HALO's P/E ratio is 17.73. In terms of profitability, IRON's ROE is -0.37%, compared to HALO's ROE of +1.26%. Regarding short-term risk, IRON is more volatile compared to HALO. This indicates higher risk in terms of short-term price fluctuations for IRON.Check HALO's competition here
Prometheus Biosciences, Inc. (NASDAQ: RXDX)
IRON vs RXDX Comparison July 2026
Disc Medicine, Inc. (NASDAQ: IRON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IRON stands at 2.8B. In comparison, RXDX has a market cap of 9.6B. Regarding current trading prices, IRON is priced at $74.12 on the NASDAQ, while RXDX trades at $199.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IRON currently has a P/E ratio of -11.20, whereas RXDX's P/E ratio is -56.47. In terms of profitability, IRON's ROE is -0.37%, compared to RXDX's ROE of -0.31%. Regarding short-term risk, IRON is more volatile compared to RXDX. This indicates higher risk in terms of short-term price fluctuations for IRON.Check RXDX's competition here
Ionis Pharmaceuticals, Inc. (NASDAQ: IONS)
IRON vs IONS Comparison July 2026
Disc Medicine, Inc. (NASDAQ: IRON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IRON stands at 2.8B. In comparison, IONS has a market cap of 9.3B. Regarding current trading prices, IRON is priced at $74.12 on the NASDAQ, while IONS trades at $56.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IRON currently has a P/E ratio of -11.20, whereas IONS's P/E ratio is -32.88. In terms of profitability, IRON's ROE is -0.37%, compared to IONS's ROE of -0.59%. Regarding short-term risk, IRON is more volatile compared to IONS. This indicates higher risk in terms of short-term price fluctuations for IRON.Check IONS's competition here
Abivax S.A. (NASDAQ: ABVX)
IRON vs ABVX Comparison July 2026
Disc Medicine, Inc. (NASDAQ: IRON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IRON stands at 2.8B. In comparison, ABVX has a market cap of 9.2B. Regarding current trading prices, IRON is priced at $74.12 on the NASDAQ, while ABVX trades at $125.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IRON currently has a P/E ratio of -11.20, whereas ABVX's P/E ratio is -65.89. In terms of profitability, IRON's ROE is -0.37%, compared to ABVX's ROE of -1.65%. Regarding short-term risk, IRON is less volatile compared to ABVX. This indicates lower risk in terms of short-term price fluctuations for IRON.Check ABVX's competition here
Nuvalent, Inc. (NASDAQ: NUVL)
IRON vs NUVL Comparison July 2026
Disc Medicine, Inc. (NASDAQ: IRON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IRON stands at 2.8B. In comparison, NUVL has a market cap of 9.1B. Regarding current trading prices, IRON is priced at $74.12 on the NASDAQ, while NUVL trades at $123.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IRON currently has a P/E ratio of -11.20, whereas NUVL's P/E ratio is -21.79. In terms of profitability, IRON's ROE is -0.37%, compared to NUVL's ROE of -0.43%. Regarding short-term risk, IRON is more volatile compared to NUVL. This indicates higher risk in terms of short-term price fluctuations for IRON.Check NUVL's competition here
Kymera Therapeutics, Inc. (NASDAQ: KYMR)
IRON vs KYMR Comparison July 2026
Disc Medicine, Inc. (NASDAQ: IRON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IRON stands at 2.8B. In comparison, KYMR has a market cap of 9.1B. Regarding current trading prices, IRON is priced at $74.12 on the NASDAQ, while KYMR trades at $110.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IRON currently has a P/E ratio of -11.20, whereas KYMR's P/E ratio is -31.32. In terms of profitability, IRON's ROE is -0.37%, compared to KYMR's ROE of -0.25%. Regarding short-term risk, IRON is less volatile compared to KYMR. This indicates lower risk in terms of short-term price fluctuations for IRON.Check KYMR's competition here
Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX)
IRON vs CRNX Comparison July 2026
Disc Medicine, Inc. (NASDAQ: IRON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IRON stands at 2.8B. In comparison, CRNX has a market cap of 8.9B. Regarding current trading prices, IRON is priced at $74.12 on the NASDAQ, while CRNX trades at $83.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IRON currently has a P/E ratio of -11.20, whereas CRNX's P/E ratio is -16.32. In terms of profitability, IRON's ROE is -0.37%, compared to CRNX's ROE of -0.44%. Regarding short-term risk, IRON is more volatile compared to CRNX. This indicates higher risk in terms of short-term price fluctuations for IRON.Check CRNX's competition here
Alkermes plc (NASDAQ: ALKS)
IRON vs ALKS Comparison July 2026
Disc Medicine, Inc. (NASDAQ: IRON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IRON stands at 2.8B. In comparison, ALKS has a market cap of 8.8B. Regarding current trading prices, IRON is priced at $74.12 on the NASDAQ, while ALKS trades at $52.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IRON currently has a P/E ratio of -11.20, whereas ALKS's P/E ratio is 55.67. In terms of profitability, IRON's ROE is -0.37%, compared to ALKS's ROE of +0.09%. Regarding short-term risk, IRON is more volatile compared to ALKS. This indicates higher risk in terms of short-term price fluctuations for IRON.Check ALKS's competition here
Protagonist Therapeutics, Inc. (NASDAQ: PTGX)
IRON vs PTGX Comparison July 2026
Disc Medicine, Inc. (NASDAQ: IRON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IRON stands at 2.8B. In comparison, PTGX has a market cap of 8.8B. Regarding current trading prices, IRON is priced at $74.12 on the NASDAQ, while PTGX trades at $136.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IRON currently has a P/E ratio of -11.20, whereas PTGX's P/E ratio is -75.20. In terms of profitability, IRON's ROE is -0.37%, compared to PTGX's ROE of -0.18%. Regarding short-term risk, IRON is more volatile compared to PTGX. This indicates higher risk in terms of short-term price fluctuations for IRON.Check PTGX's competition here
ImmunoGen, Inc. (NASDAQ: IMGN)
IRON vs IMGN Comparison July 2026
Disc Medicine, Inc. (NASDAQ: IRON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IRON stands at 2.8B. In comparison, IMGN has a market cap of 8.7B. Regarding current trading prices, IRON is priced at $74.12 on the NASDAQ, while IMGN trades at $31.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IRON currently has a P/E ratio of -11.20, whereas IMGN's P/E ratio is -111.55. In terms of profitability, IRON's ROE is -0.37%, compared to IMGN's ROE of -0.93%. Regarding short-term risk, IRON is more volatile compared to IMGN. This indicates higher risk in terms of short-term price fluctuations for IRON.Check IMGN's competition here
TG Therapeutics, Inc. (NASDAQ: TGTX)
IRON vs TGTX Comparison July 2026
Disc Medicine, Inc. (NASDAQ: IRON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IRON stands at 2.8B. In comparison, TGTX has a market cap of 8.6B. Regarding current trading prices, IRON is priced at $74.12 on the NASDAQ, while TGTX trades at $56.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IRON currently has a P/E ratio of -11.20, whereas TGTX's P/E ratio is 19.26. In terms of profitability, IRON's ROE is -0.37%, compared to TGTX's ROE of +0.87%. Regarding short-term risk, IRON is less volatile compared to TGTX. This indicates lower risk in terms of short-term price fluctuations for IRON.Check TGTX's competition here
Blueprint Medicines Corporation (NASDAQ: BPMC)
IRON vs BPMC Comparison July 2026
Disc Medicine, Inc. (NASDAQ: IRON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IRON stands at 2.8B. In comparison, BPMC has a market cap of 8.4B. Regarding current trading prices, IRON is priced at $74.12 on the NASDAQ, while BPMC trades at $129.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IRON currently has a P/E ratio of -11.20, whereas BPMC's P/E ratio is -51.58. In terms of profitability, IRON's ROE is -0.37%, compared to BPMC's ROE of -0.31%. Regarding short-term risk, IRON is more volatile compared to BPMC. This indicates higher risk in terms of short-term price fluctuations for IRON.Check BPMC's competition here
Apogee Therapeutics, Inc. (NASDAQ: APGE)
IRON vs APGE Comparison July 2026
Disc Medicine, Inc. (NASDAQ: IRON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IRON stands at 2.8B. In comparison, APGE has a market cap of 8.3B. Regarding current trading prices, IRON is priced at $74.12 on the NASDAQ, while APGE trades at $134.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IRON currently has a P/E ratio of -11.20, whereas APGE's P/E ratio is -31.01. In terms of profitability, IRON's ROE is -0.37%, compared to APGE's ROE of -0.33%. Regarding short-term risk, IRON is more volatile compared to APGE. This indicates higher risk in terms of short-term price fluctuations for IRON.Check APGE's competition here
Cerevel Therapeutics Holdings, Inc. (NASDAQ: CERE)
IRON vs CERE Comparison July 2026
Disc Medicine, Inc. (NASDAQ: IRON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IRON stands at 2.8B. In comparison, CERE has a market cap of 8.2B. Regarding current trading prices, IRON is priced at $74.12 on the NASDAQ, while CERE trades at $44.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IRON currently has a P/E ratio of -11.20, whereas CERE's P/E ratio is -16.47. In terms of profitability, IRON's ROE is -0.37%, compared to CERE's ROE of -0.72%. Regarding short-term risk, IRON is more volatile compared to CERE. This indicates higher risk in terms of short-term price fluctuations for IRON.Check CERE's competition here
Immunovant, Inc. (NASDAQ: IMVT)
IRON vs IMVT Comparison July 2026
Disc Medicine, Inc. (NASDAQ: IRON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IRON stands at 2.8B. In comparison, IMVT has a market cap of 8.1B. Regarding current trading prices, IRON is priced at $74.12 on the NASDAQ, while IMVT trades at $39.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IRON currently has a P/E ratio of -11.20, whereas IMVT's P/E ratio is -14.76. In terms of profitability, IRON's ROE is -0.37%, compared to IMVT's ROE of -0.68%. Regarding short-term risk, IRON is more volatile compared to IMVT. This indicates higher risk in terms of short-term price fluctuations for IRON.Check IMVT's competition here
Vaxcyte, Inc. (NASDAQ: PCVX)
IRON vs PCVX Comparison July 2026
Disc Medicine, Inc. (NASDAQ: IRON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IRON stands at 2.8B. In comparison, PCVX has a market cap of 7.9B. Regarding current trading prices, IRON is priced at $74.12 on the NASDAQ, while PCVX trades at $54.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IRON currently has a P/E ratio of -11.20, whereas PCVX's P/E ratio is -7.94. In terms of profitability, IRON's ROE is -0.37%, compared to PCVX's ROE of -0.33%. Regarding short-term risk, IRON is more volatile compared to PCVX. This indicates higher risk in terms of short-term price fluctuations for IRON.Check PCVX's competition here
ImmunityBio, Inc. (NASDAQ: IBRX)
IRON vs IBRX Comparison July 2026
Disc Medicine, Inc. (NASDAQ: IRON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IRON stands at 2.8B. In comparison, IBRX has a market cap of 7.4B. Regarding current trading prices, IRON is priced at $74.12 on the NASDAQ, while IBRX trades at $7.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IRON currently has a P/E ratio of -11.20, whereas IBRX's P/E ratio is -8.35. In terms of profitability, IRON's ROE is -0.37%, compared to IBRX's ROE of +1.39%. Regarding short-term risk, IRON is less volatile compared to IBRX. This indicates lower risk in terms of short-term price fluctuations for IRON.Check IBRX's competition here
Metsera, Inc. (NASDAQ: MTSR)
IRON vs MTSR Comparison July 2026
Disc Medicine, Inc. (NASDAQ: IRON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IRON stands at 2.8B. In comparison, MTSR has a market cap of 7.4B. Regarding current trading prices, IRON is priced at $74.12 on the NASDAQ, while MTSR trades at $70.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IRON currently has a P/E ratio of -11.20, whereas MTSR's P/E ratio is -23.58. In terms of profitability, IRON's ROE is -0.37%, compared to MTSR's ROE of -0.61%. Regarding short-term risk, IRON is more volatile compared to MTSR. This indicates higher risk in terms of short-term price fluctuations for IRON.Check MTSR's competition here
Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM)
IRON vs RYTM Comparison July 2026
Disc Medicine, Inc. (NASDAQ: IRON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IRON stands at 2.8B. In comparison, RYTM has a market cap of 7B. Regarding current trading prices, IRON is priced at $74.12 on the NASDAQ, while RYTM trades at $102.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IRON currently has a P/E ratio of -11.20, whereas RYTM's P/E ratio is -32.62. In terms of profitability, IRON's ROE is -0.37%, compared to RYTM's ROE of -2.03%. Regarding short-term risk, IRON is more volatile compared to RYTM. This indicates higher risk in terms of short-term price fluctuations for IRON.Check RYTM's competition here
Praxis Precision Medicines, Inc. (NASDAQ: PRAX)
IRON vs PRAX Comparison July 2026
Disc Medicine, Inc. (NASDAQ: IRON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IRON stands at 2.8B. In comparison, PRAX has a market cap of 6.9B. Regarding current trading prices, IRON is priced at $74.12 on the NASDAQ, while PRAX trades at $325.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IRON currently has a P/E ratio of -11.20, whereas PRAX's P/E ratio is -24.33. In terms of profitability, IRON's ROE is -0.37%, compared to PRAX's ROE of -0.43%. Regarding short-term risk, IRON is less volatile compared to PRAX. This indicates lower risk in terms of short-term price fluctuations for IRON.Check PRAX's competition here
Merus N.V. (NASDAQ: MRUS)
IRON vs MRUS Comparison July 2026
Disc Medicine, Inc. (NASDAQ: IRON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IRON stands at 2.8B. In comparison, MRUS has a market cap of 6.8B. Regarding current trading prices, IRON is priced at $74.12 on the NASDAQ, while MRUS trades at $90.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IRON currently has a P/E ratio of -11.20, whereas MRUS's P/E ratio is -17.05. In terms of profitability, IRON's ROE is -0.37%, compared to MRUS's ROE of -0.46%. Regarding short-term risk, IRON is more volatile compared to MRUS. This indicates higher risk in terms of short-term price fluctuations for IRON.Check MRUS's competition here
Cogent Biosciences, Inc. (NASDAQ: COGT)
IRON vs COGT Comparison July 2026
Disc Medicine, Inc. (NASDAQ: IRON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IRON stands at 2.8B. In comparison, COGT has a market cap of 6.8B. Regarding current trading prices, IRON is priced at $74.12 on the NASDAQ, while COGT trades at $39.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IRON currently has a P/E ratio of -11.20, whereas COGT's P/E ratio is -18.84. In terms of profitability, IRON's ROE is -0.37%, compared to COGT's ROE of -0.83%. Regarding short-term risk, IRON is more volatile compared to COGT. This indicates higher risk in terms of short-term price fluctuations for IRON.Check COGT's competition here
Arcellx, Inc. (NASDAQ: ACLX)
IRON vs ACLX Comparison July 2026
Disc Medicine, Inc. (NASDAQ: IRON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IRON stands at 2.8B. In comparison, ACLX has a market cap of 6.7B. Regarding current trading prices, IRON is priced at $74.12 on the NASDAQ, while ACLX trades at $115.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IRON currently has a P/E ratio of -11.20, whereas ACLX's P/E ratio is -28.27. In terms of profitability, IRON's ROE is -0.37%, compared to ACLX's ROE of -0.55%. Regarding short-term risk, IRON is more volatile compared to ACLX. This indicates higher risk in terms of short-term price fluctuations for IRON.Check ACLX's competition here
Erasca, Inc. (NASDAQ: ERAS)
IRON vs ERAS Comparison July 2026
Disc Medicine, Inc. (NASDAQ: IRON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IRON stands at 2.8B. In comparison, ERAS has a market cap of 6.6B. Regarding current trading prices, IRON is priced at $74.12 on the NASDAQ, while ERAS trades at $19.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IRON currently has a P/E ratio of -11.20, whereas ERAS's P/E ratio is -20.55. In terms of profitability, IRON's ROE is -0.37%, compared to ERAS's ROE of -0.77%. Regarding short-term risk, IRON is less volatile compared to ERAS. This indicates lower risk in terms of short-term price fluctuations for IRON.Check ERAS's competition here
Reata Pharmaceuticals, Inc. (NASDAQ: RETA)
IRON vs RETA Comparison July 2026
Disc Medicine, Inc. (NASDAQ: IRON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IRON stands at 2.8B. In comparison, RETA has a market cap of 6.6B. Regarding current trading prices, IRON is priced at $74.12 on the NASDAQ, while RETA trades at $172.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IRON currently has a P/E ratio of -11.20, whereas RETA's P/E ratio is -66.29. In terms of profitability, IRON's ROE is -0.37%, compared to RETA's ROE of +0.47%. Regarding short-term risk, IRON is more volatile compared to RETA. This indicates higher risk in terms of short-term price fluctuations for IRON.Check RETA's competition here
PTC Therapeutics, Inc. (NASDAQ: PTCT)
IRON vs PTCT Comparison July 2026
Disc Medicine, Inc. (NASDAQ: IRON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IRON stands at 2.8B. In comparison, PTCT has a market cap of 6.4B. Regarding current trading prices, IRON is priced at $74.12 on the NASDAQ, while PTCT trades at $76.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IRON currently has a P/E ratio of -11.20, whereas PTCT's P/E ratio is -32.97. In terms of profitability, IRON's ROE is -0.37%, compared to PTCT's ROE of +1.00%. Regarding short-term risk, IRON is more volatile compared to PTCT. This indicates higher risk in terms of short-term price fluctuations for IRON.Check PTCT's competition here
Centessa Pharmaceuticals plc (NASDAQ: CNTA)
IRON vs CNTA Comparison July 2026
Disc Medicine, Inc. (NASDAQ: IRON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IRON stands at 2.8B. In comparison, CNTA has a market cap of 6.3B. Regarding current trading prices, IRON is priced at $74.12 on the NASDAQ, while CNTA trades at $40.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IRON currently has a P/E ratio of -11.20, whereas CNTA's P/E ratio is -22.63. In terms of profitability, IRON's ROE is -0.37%, compared to CNTA's ROE of -0.60%. Regarding short-term risk, IRON is more volatile compared to CNTA. This indicates higher risk in terms of short-term price fluctuations for IRON.Check CNTA's competition here
Spyre Therapeutics, Inc. (NASDAQ: SYRE)
IRON vs SYRE Comparison July 2026
Disc Medicine, Inc. (NASDAQ: IRON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IRON stands at 2.8B. In comparison, SYRE has a market cap of 6.2B. Regarding current trading prices, IRON is priced at $74.12 on the NASDAQ, while SYRE trades at $102.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IRON currently has a P/E ratio of -11.20, whereas SYRE's P/E ratio is -49.10. In terms of profitability, IRON's ROE is -0.37%, compared to SYRE's ROE of -0.31%. Regarding short-term risk, IRON is less volatile compared to SYRE. This indicates lower risk in terms of short-term price fluctuations for IRON.Check SYRE's competition here
Belite Bio, Inc (NASDAQ: BLTE)
IRON vs BLTE Comparison July 2026
Disc Medicine, Inc. (NASDAQ: IRON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IRON stands at 2.8B. In comparison, BLTE has a market cap of 6.1B. Regarding current trading prices, IRON is priced at $74.12 on the NASDAQ, while BLTE trades at $153.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IRON currently has a P/E ratio of -11.20, whereas BLTE's P/E ratio is -82.01. In terms of profitability, IRON's ROE is -0.37%, compared to BLTE's ROE of -0.18%. Regarding short-term risk, IRON is more volatile compared to BLTE. This indicates higher risk in terms of short-term price fluctuations for IRON.Check BLTE's competition here
CG Oncology Inc. (NASDAQ: CGON)
IRON vs CGON Comparison July 2026
Disc Medicine, Inc. (NASDAQ: IRON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IRON stands at 2.8B. In comparison, CGON has a market cap of 6.1B. Regarding current trading prices, IRON is priced at $74.12 on the NASDAQ, while CGON trades at $69.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IRON currently has a P/E ratio of -11.20, whereas CGON's P/E ratio is -29.75. In terms of profitability, IRON's ROE is -0.37%, compared to CGON's ROE of -0.23%. Regarding short-term risk, IRON is more volatile compared to CGON. This indicates higher risk in terms of short-term price fluctuations for IRON.Check CGON's competition here
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND)
IRON vs LGND Comparison July 2026
Disc Medicine, Inc. (NASDAQ: IRON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IRON stands at 2.8B. In comparison, LGND has a market cap of 6B. Regarding current trading prices, IRON is priced at $74.12 on the NASDAQ, while LGND trades at $300.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IRON currently has a P/E ratio of -11.20, whereas LGND's P/E ratio is 36.03. In terms of profitability, IRON's ROE is -0.37%, compared to LGND's ROE of +0.16%. Regarding short-term risk, IRON is more volatile compared to LGND. This indicates higher risk in terms of short-term price fluctuations for IRON.Check LGND's competition here
Scholar Rock Holding Corporation (NASDAQ: SRRK)
IRON vs SRRK Comparison July 2026
Disc Medicine, Inc. (NASDAQ: IRON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IRON stands at 2.8B. In comparison, SRRK has a market cap of 5.7B. Regarding current trading prices, IRON is priced at $74.12 on the NASDAQ, while SRRK trades at $47.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IRON currently has a P/E ratio of -11.20, whereas SRRK's P/E ratio is -13.28. In terms of profitability, IRON's ROE is -0.37%, compared to SRRK's ROE of -1.64%. Regarding short-term risk, IRON is less volatile compared to SRRK. This indicates lower risk in terms of short-term price fluctuations for IRON.Check SRRK's competition here
Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM)
IRON vs MIRM Comparison July 2026
Disc Medicine, Inc. (NASDAQ: IRON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IRON stands at 2.8B. In comparison, MIRM has a market cap of 5.7B. Regarding current trading prices, IRON is priced at $74.12 on the NASDAQ, while MIRM trades at $113.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IRON currently has a P/E ratio of -11.20, whereas MIRM's P/E ratio is -8.30. In terms of profitability, IRON's ROE is -0.37%, compared to MIRM's ROE of -2.89%. Regarding short-term risk, IRON is more volatile compared to MIRM. This indicates higher risk in terms of short-term price fluctuations for IRON.Check MIRM's competition here
Cidara Therapeutics, Inc. (NASDAQ: CDTX)
IRON vs CDTX Comparison July 2026
Disc Medicine, Inc. (NASDAQ: IRON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IRON stands at 2.8B. In comparison, CDTX has a market cap of 5.6B. Regarding current trading prices, IRON is priced at $74.12 on the NASDAQ, while CDTX trades at $221.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IRON currently has a P/E ratio of -11.20, whereas CDTX's P/E ratio is -19.77. In terms of profitability, IRON's ROE is -0.37%, compared to CDTX's ROE of -0.37%. Regarding short-term risk, IRON is more volatile compared to CDTX. This indicates higher risk in terms of short-term price fluctuations for IRON.Check CDTX's competition here
Abcam plc (NASDAQ: ABCM)
IRON vs ABCM Comparison July 2026
Disc Medicine, Inc. (NASDAQ: IRON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IRON stands at 2.8B. In comparison, ABCM has a market cap of 5.5B. Regarding current trading prices, IRON is priced at $74.12 on the NASDAQ, while ABCM trades at $23.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IRON currently has a P/E ratio of -11.20, whereas ABCM's P/E ratio is 2399.00. In terms of profitability, IRON's ROE is -0.37%, compared to ABCM's ROE of -0.01%. Regarding short-term risk, IRON is more volatile compared to ABCM. This indicates higher risk in terms of short-term price fluctuations for IRON.Check ABCM's competition here
IVERIC bio, Inc. (NASDAQ: ISEE)
IRON vs ISEE Comparison July 2026
Disc Medicine, Inc. (NASDAQ: IRON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IRON stands at 2.8B. In comparison, ISEE has a market cap of 5.5B. Regarding current trading prices, IRON is priced at $74.12 on the NASDAQ, while ISEE trades at $39.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IRON currently has a P/E ratio of -11.20, whereas ISEE's P/E ratio is -22.44. In terms of profitability, IRON's ROE is -0.37%, compared to ISEE's ROE of -0.39%. Regarding short-term risk, IRON is more volatile compared to ISEE. This indicates higher risk in terms of short-term price fluctuations for IRON.Check ISEE's competition here
Travere Therapeutics, Inc. (NASDAQ: TVTX)
IRON vs TVTX Comparison July 2026
Disc Medicine, Inc. (NASDAQ: IRON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IRON stands at 2.8B. In comparison, TVTX has a market cap of 5.3B. Regarding current trading prices, IRON is priced at $74.12 on the NASDAQ, while TVTX trades at $57.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IRON currently has a P/E ratio of -11.20, whereas TVTX's P/E ratio is -260.73. In terms of profitability, IRON's ROE is -0.37%, compared to TVTX's ROE of -0.27%. Regarding short-term risk, IRON is more volatile compared to TVTX. This indicates higher risk in terms of short-term price fluctuations for IRON.Check TVTX's competition here
Apellis Pharmaceuticals, Inc. (NASDAQ: APLS)
IRON vs APLS Comparison July 2026
Disc Medicine, Inc. (NASDAQ: IRON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IRON stands at 2.8B. In comparison, APLS has a market cap of 5.3B. Regarding current trading prices, IRON is priced at $74.12 on the NASDAQ, while APLS trades at $41.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IRON currently has a P/E ratio of -11.20, whereas APLS's P/E ratio is 38.35. In terms of profitability, IRON's ROE is -0.37%, compared to APLS's ROE of +0.40%. Regarding short-term risk, IRON is more volatile compared to APLS. This indicates higher risk in terms of short-term price fluctuations for IRON.Check APLS's competition here
Xenon Pharmaceuticals Inc. (NASDAQ: XENE)
IRON vs XENE Comparison July 2026
Disc Medicine, Inc. (NASDAQ: IRON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IRON stands at 2.8B. In comparison, XENE has a market cap of 5.2B. Regarding current trading prices, IRON is priced at $74.12 on the NASDAQ, while XENE trades at $65.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IRON currently has a P/E ratio of -11.20, whereas XENE's P/E ratio is -13.92. In terms of profitability, IRON's ROE is -0.37%, compared to XENE's ROE of -0.49%. Regarding short-term risk, IRON is more volatile compared to XENE. This indicates higher risk in terms of short-term price fluctuations for IRON.Check XENE's competition here
Terns Pharmaceuticals, Inc. (NASDAQ: TERN)
IRON vs TERN Comparison July 2026
Disc Medicine, Inc. (NASDAQ: IRON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IRON stands at 2.8B. In comparison, TERN has a market cap of 4.8B. Regarding current trading prices, IRON is priced at $74.12 on the NASDAQ, while TERN trades at $52.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IRON currently has a P/E ratio of -11.20, whereas TERN's P/E ratio is -51.41. In terms of profitability, IRON's ROE is -0.37%, compared to TERN's ROE of -0.20%. Regarding short-term risk, IRON is more volatile compared to TERN. This indicates higher risk in terms of short-term price fluctuations for IRON.Check TERN's competition here
Definium Therapeutics, Inc. (NASDAQ: DFTX)
IRON vs DFTX Comparison July 2026
Disc Medicine, Inc. (NASDAQ: IRON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IRON stands at 2.8B. In comparison, DFTX has a market cap of 4.7B. Regarding current trading prices, IRON is priced at $74.12 on the NASDAQ, while DFTX trades at $43.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IRON currently has a P/E ratio of -11.20, whereas DFTX's P/E ratio is N/A. In terms of profitability, IRON's ROE is -0.37%, compared to DFTX's ROE of -1.02%. Regarding short-term risk, IRON is more volatile compared to DFTX. This indicates higher risk in terms of short-term price fluctuations for IRON.Check DFTX's competition here
Veradermics, Incorporated (NYSE: MANE)
IRON vs MANE Comparison July 2026
Disc Medicine, Inc. (NASDAQ: IRON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IRON stands at 2.8B. In comparison, MANE has a market cap of 4.6B. Regarding current trading prices, IRON is priced at $74.12 on the NASDAQ, while MANE trades at $109.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IRON currently has a P/E ratio of -11.20, whereas MANE's P/E ratio is -34.92. In terms of profitability, IRON's ROE is -0.37%, compared to MANE's ROE of -0.84%. Regarding short-term risk, IRON is less volatile compared to MANE. This indicates lower risk in terms of short-term price fluctuations for IRON.Check MANE's competition here
Amicus Therapeutics, Inc. (NASDAQ: FOLD)
IRON vs FOLD Comparison July 2026
Disc Medicine, Inc. (NASDAQ: IRON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IRON stands at 2.8B. In comparison, FOLD has a market cap of 4.5B. Regarding current trading prices, IRON is priced at $74.12 on the NASDAQ, while FOLD trades at $14.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IRON currently has a P/E ratio of -11.20, whereas FOLD's P/E ratio is -161.00. In terms of profitability, IRON's ROE is -0.37%, compared to FOLD's ROE of -0.12%. Regarding short-term risk, IRON is more volatile compared to FOLD. This indicates higher risk in terms of short-term price fluctuations for IRON.Check FOLD's competition here
Akero Therapeutics, Inc. (NASDAQ: AKRO)
IRON vs AKRO Comparison July 2026
Disc Medicine, Inc. (NASDAQ: IRON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IRON stands at 2.8B. In comparison, AKRO has a market cap of 4.5B. Regarding current trading prices, IRON is priced at $74.12 on the NASDAQ, while AKRO trades at $54.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IRON currently has a P/E ratio of -11.20, whereas AKRO's P/E ratio is -14.57. In terms of profitability, IRON's ROE is -0.37%, compared to AKRO's ROE of -0.22%. Regarding short-term risk, IRON is more volatile compared to AKRO. This indicates higher risk in terms of short-term price fluctuations for IRON.Check AKRO's competition here
CRISPR Therapeutics AG (NASDAQ: CRSP)
IRON vs CRSP Comparison July 2026
Disc Medicine, Inc. (NASDAQ: IRON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IRON stands at 2.8B. In comparison, CRSP has a market cap of 4.5B. Regarding current trading prices, IRON is priced at $74.12 on the NASDAQ, while CRSP trades at $46.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IRON currently has a P/E ratio of -11.20, whereas CRSP's P/E ratio is -9.11. In terms of profitability, IRON's ROE is -0.37%, compared to CRSP's ROE of -0.31%. Regarding short-term risk, IRON is less volatile compared to CRSP. This indicates lower risk in terms of short-term price fluctuations for IRON.Check CRSP's competition here
Alpine Immune Sciences, Inc. (NASDAQ: ALPN)
IRON vs ALPN Comparison July 2026
Disc Medicine, Inc. (NASDAQ: IRON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IRON stands at 2.8B. In comparison, ALPN has a market cap of 4.5B. Regarding current trading prices, IRON is priced at $74.12 on the NASDAQ, while ALPN trades at $64.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IRON currently has a P/E ratio of -11.20, whereas ALPN's P/E ratio is -101.52. In terms of profitability, IRON's ROE is -0.37%, compared to ALPN's ROE of -0.13%. Regarding short-term risk, IRON is more volatile compared to ALPN. This indicates higher risk in terms of short-term price fluctuations for IRON.Check ALPN's competition here
Edgewise Therapeutics, Inc. (NASDAQ: EWTX)
IRON vs EWTX Comparison July 2026
Disc Medicine, Inc. (NASDAQ: IRON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IRON stands at 2.8B. In comparison, EWTX has a market cap of 4.4B. Regarding current trading prices, IRON is priced at $74.12 on the NASDAQ, while EWTX trades at $40.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IRON currently has a P/E ratio of -11.20, whereas EWTX's P/E ratio is -24.60. In terms of profitability, IRON's ROE is -0.37%, compared to EWTX's ROE of -0.33%. Regarding short-term risk, IRON is less volatile compared to EWTX. This indicates lower risk in terms of short-term price fluctuations for IRON.Check EWTX's competition here
Caris Life Sciences, Inc. (NASDAQ: CAI)
IRON vs CAI Comparison July 2026
Disc Medicine, Inc. (NASDAQ: IRON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IRON stands at 2.8B. In comparison, CAI has a market cap of 4.4B. Regarding current trading prices, IRON is priced at $74.12 on the NASDAQ, while CAI trades at $15.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IRON currently has a P/E ratio of -11.20, whereas CAI's P/E ratio is -85.37. In terms of profitability, IRON's ROE is -0.37%, compared to CAI's ROE of +0.06%. Regarding short-term risk, IRON is less volatile compared to CAI. This indicates lower risk in terms of short-term price fluctuations for IRON.Check CAI's competition here
Dianthus Therapeutics, Inc. (NASDAQ: DNTH)
IRON vs DNTH Comparison July 2026
Disc Medicine, Inc. (NASDAQ: IRON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IRON stands at 2.8B. In comparison, DNTH has a market cap of 4.3B. Regarding current trading prices, IRON is priced at $74.12 on the NASDAQ, while DNTH trades at $103.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IRON currently has a P/E ratio of -11.20, whereas DNTH's P/E ratio is -25.15. In terms of profitability, IRON's ROE is -0.37%, compared to DNTH's ROE of -0.02%. Regarding short-term risk, IRON is more volatile compared to DNTH. This indicates higher risk in terms of short-term price fluctuations for IRON.Check DNTH's competition here
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD)
IRON vs ACAD Comparison July 2026
Disc Medicine, Inc. (NASDAQ: IRON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IRON stands at 2.8B. In comparison, ACAD has a market cap of 4.3B. Regarding current trading prices, IRON is priced at $74.12 on the NASDAQ, while ACAD trades at $24.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IRON currently has a P/E ratio of -11.20, whereas ACAD's P/E ratio is 12.18. In terms of profitability, IRON's ROE is -0.37%, compared to ACAD's ROE of +0.36%. Regarding short-term risk, IRON is more volatile compared to ACAD. This indicates higher risk in terms of short-term price fluctuations for IRON.Check ACAD's competition here
Opthea Limited (NASDAQ: OPT)
IRON vs OPT Comparison July 2026
Disc Medicine, Inc. (NASDAQ: IRON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IRON stands at 2.8B. In comparison, OPT has a market cap of 4.2B. Regarding current trading prices, IRON is priced at $74.12 on the NASDAQ, while OPT trades at $3.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IRON currently has a P/E ratio of -11.20, whereas OPT's P/E ratio is -1.52. In terms of profitability, IRON's ROE is -0.37%, compared to OPT's ROE of +1.18%. Regarding short-term risk, IRON is more volatile compared to OPT. This indicates higher risk in terms of short-term price fluctuations for IRON.Check OPT's competition here
Mirati Therapeutics, Inc. (NASDAQ: MRTX)
IRON vs MRTX Comparison July 2026
Disc Medicine, Inc. (NASDAQ: IRON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IRON stands at 2.8B. In comparison, MRTX has a market cap of 4.1B. Regarding current trading prices, IRON is priced at $74.12 on the NASDAQ, while MRTX trades at $58.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IRON currently has a P/E ratio of -11.20, whereas MRTX's P/E ratio is -4.82. In terms of profitability, IRON's ROE is -0.37%, compared to MRTX's ROE of -0.62%. Regarding short-term risk, IRON is more volatile compared to MRTX. This indicates higher risk in terms of short-term price fluctuations for IRON.Check MRTX's competition here
Legend Biotech Corporation (NASDAQ: LEGN)
IRON vs LEGN Comparison July 2026
Disc Medicine, Inc. (NASDAQ: IRON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IRON stands at 2.8B. In comparison, LEGN has a market cap of 4.1B. Regarding current trading prices, IRON is priced at $74.12 on the NASDAQ, while LEGN trades at $22.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IRON currently has a P/E ratio of -11.20, whereas LEGN's P/E ratio is -32.68. In terms of profitability, IRON's ROE is -0.37%, compared to LEGN's ROE of -0.25%. Regarding short-term risk, IRON is less volatile compared to LEGN. This indicates lower risk in terms of short-term price fluctuations for IRON.Check LEGN's competition here
Dyne Therapeutics, Inc. (NASDAQ: DYN)
IRON vs DYN Comparison July 2026
Disc Medicine, Inc. (NASDAQ: IRON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IRON stands at 2.8B. In comparison, DYN has a market cap of 4B. Regarding current trading prices, IRON is priced at $74.12 on the NASDAQ, while DYN trades at $24.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IRON currently has a P/E ratio of -11.20, whereas DYN's P/E ratio is -7.59. In terms of profitability, IRON's ROE is -0.37%, compared to DYN's ROE of -0.58%. Regarding short-term risk, IRON is less volatile compared to DYN. This indicates lower risk in terms of short-term price fluctuations for IRON.Check DYN's competition here
Viking Therapeutics, Inc. (NASDAQ: VKTX)
IRON vs VKTX Comparison July 2026
Disc Medicine, Inc. (NASDAQ: IRON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IRON stands at 2.8B. In comparison, VKTX has a market cap of 4B. Regarding current trading prices, IRON is priced at $74.12 on the NASDAQ, while VKTX trades at $34.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IRON currently has a P/E ratio of -11.20, whereas VKTX's P/E ratio is -8.40. In terms of profitability, IRON's ROE is -0.37%, compared to VKTX's ROE of -0.71%. Regarding short-term risk, IRON is similarly volatile compared to VKTX. This indicates similar risk in terms of short-term price fluctuations for IRON.Check VKTX's competition here
Celcuity Inc. (NASDAQ: CELC)
IRON vs CELC Comparison July 2026
Disc Medicine, Inc. (NASDAQ: IRON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IRON stands at 2.8B. In comparison, CELC has a market cap of 4B. Regarding current trading prices, IRON is priced at $74.12 on the NASDAQ, while CELC trades at $82.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IRON currently has a P/E ratio of -11.20, whereas CELC's P/E ratio is -21.18. In terms of profitability, IRON's ROE is -0.37%, compared to CELC's ROE of -2.45%. Regarding short-term risk, IRON is less volatile compared to CELC. This indicates lower risk in terms of short-term price fluctuations for IRON.Check CELC's competition here
Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX)
IRON vs CPRX Comparison July 2026
Disc Medicine, Inc. (NASDAQ: IRON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IRON stands at 2.8B. In comparison, CPRX has a market cap of 3.9B. Regarding current trading prices, IRON is priced at $74.12 on the NASDAQ, while CPRX trades at $31.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IRON currently has a P/E ratio of -11.20, whereas CPRX's P/E ratio is 12.30. In terms of profitability, IRON's ROE is -0.37%, compared to CPRX's ROE of +0.24%. Regarding short-term risk, IRON is more volatile compared to CPRX. This indicates higher risk in terms of short-term price fluctuations for IRON.Check CPRX's competition here
Enliven Therapeutics, Inc. (NASDAQ: ELVN)
IRON vs ELVN Comparison July 2026
Disc Medicine, Inc. (NASDAQ: IRON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IRON stands at 2.8B. In comparison, ELVN has a market cap of 3.8B. Regarding current trading prices, IRON is priced at $74.12 on the NASDAQ, while ELVN trades at $52.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IRON currently has a P/E ratio of -11.20, whereas ELVN's P/E ratio is -31.71. In terms of profitability, IRON's ROE is -0.37%, compared to ELVN's ROE of -0.21%. Regarding short-term risk, IRON is more volatile compared to ELVN. This indicates higher risk in terms of short-term price fluctuations for IRON.Check ELVN's competition here
RayzeBio, Inc. Common Stock (NASDAQ: RYZB)
IRON vs RYZB Comparison July 2026
Disc Medicine, Inc. (NASDAQ: IRON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IRON stands at 2.8B. In comparison, RYZB has a market cap of 3.8B. Regarding current trading prices, IRON is priced at $74.12 on the NASDAQ, while RYZB trades at $62.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IRON currently has a P/E ratio of -11.20, whereas RYZB's P/E ratio is -57.86. In terms of profitability, IRON's ROE is -0.37%, compared to RYZB's ROE of +0.83%. Regarding short-term risk, IRON is more volatile compared to RYZB. This indicates higher risk in terms of short-term price fluctuations for IRON.Check RYZB's competition here
CymaBay Therapeutics, Inc. (NASDAQ: CBAY)
IRON vs CBAY Comparison July 2026
Disc Medicine, Inc. (NASDAQ: IRON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IRON stands at 2.8B. In comparison, CBAY has a market cap of 3.7B. Regarding current trading prices, IRON is priced at $74.12 on the NASDAQ, while CBAY trades at $32.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IRON currently has a P/E ratio of -11.20, whereas CBAY's P/E ratio is -32.81. In terms of profitability, IRON's ROE is -0.37%, compared to CBAY's ROE of -0.64%. Regarding short-term risk, IRON is more volatile compared to CBAY. This indicates higher risk in terms of short-term price fluctuations for IRON.Check CBAY's competition here
Denali Therapeutics Inc. (NASDAQ: DNLI)
IRON vs DNLI Comparison July 2026
Disc Medicine, Inc. (NASDAQ: IRON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IRON stands at 2.8B. In comparison, DNLI has a market cap of 3.7B. Regarding current trading prices, IRON is priced at $74.12 on the NASDAQ, while DNLI trades at $23.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IRON currently has a P/E ratio of -11.20, whereas DNLI's P/E ratio is -8.02. In terms of profitability, IRON's ROE is -0.37%, compared to DNLI's ROE of -0.52%. Regarding short-term risk, IRON is less volatile compared to DNLI. This indicates lower risk in terms of short-term price fluctuations for IRON.Check DNLI's competition here
NewAmsterdam Pharma Company N.V. (NASDAQ: NAMSW)
IRON vs NAMSW Comparison July 2026
Disc Medicine, Inc. (NASDAQ: IRON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IRON stands at 2.8B. In comparison, NAMSW has a market cap of 3.6B. Regarding current trading prices, IRON is priced at $74.12 on the NASDAQ, while NAMSW trades at $19.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IRON currently has a P/E ratio of -11.20, whereas NAMSW's P/E ratio is -10.50. In terms of profitability, IRON's ROE is -0.37%, compared to NAMSW's ROE of -0.30%. Regarding short-term risk, IRON is less volatile compared to NAMSW. This indicates lower risk in terms of short-term price fluctuations for IRON.Check NAMSW's competition here
Adaptive Biotechnologies Corporation (NASDAQ: ADPT)
IRON vs ADPT Comparison July 2026
Disc Medicine, Inc. (NASDAQ: IRON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IRON stands at 2.8B. In comparison, ADPT has a market cap of 3.6B. Regarding current trading prices, IRON is priced at $74.12 on the NASDAQ, while ADPT trades at $22.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IRON currently has a P/E ratio of -11.20, whereas ADPT's P/E ratio is -41.24. In terms of profitability, IRON's ROE is -0.37%, compared to ADPT's ROE of -0.24%. Regarding short-term risk, IRON is less volatile compared to ADPT. This indicates lower risk in terms of short-term price fluctuations for IRON.Check ADPT's competition here
SpringWorks Therapeutics, Inc. (NASDAQ: SWTX)
IRON vs SWTX Comparison July 2026
Disc Medicine, Inc. (NASDAQ: IRON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IRON stands at 2.8B. In comparison, SWTX has a market cap of 3.5B. Regarding current trading prices, IRON is priced at $74.12 on the NASDAQ, while SWTX trades at $46.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IRON currently has a P/E ratio of -11.20, whereas SWTX's P/E ratio is -13.78. In terms of profitability, IRON's ROE is -0.37%, compared to SWTX's ROE of -0.47%. Regarding short-term risk, IRON is more volatile compared to SWTX. This indicates higher risk in terms of short-term price fluctuations for IRON.Check SWTX's competition here
NewAmsterdam Pharma Company N.V. (NASDAQ: NAMS)
IRON vs NAMS Comparison July 2026
Disc Medicine, Inc. (NASDAQ: IRON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IRON stands at 2.8B. In comparison, NAMS has a market cap of 3.5B. Regarding current trading prices, IRON is priced at $74.12 on the NASDAQ, while NAMS trades at $29.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IRON currently has a P/E ratio of -11.20, whereas NAMS's P/E ratio is -18.64. In terms of profitability, IRON's ROE is -0.37%, compared to NAMS's ROE of -0.30%. Regarding short-term risk, IRON is less volatile compared to NAMS. This indicates lower risk in terms of short-term price fluctuations for IRON.Check NAMS's competition here
Telix Pharmaceuticals Limited (NASDAQ: TLX)
IRON vs TLX Comparison July 2026
Disc Medicine, Inc. (NASDAQ: IRON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IRON stands at 2.8B. In comparison, TLX has a market cap of 3.5B. Regarding current trading prices, IRON is priced at $74.12 on the NASDAQ, while TLX trades at $10.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IRON currently has a P/E ratio of -11.20, whereas TLX's P/E ratio is -555.43. In terms of profitability, IRON's ROE is -0.37%, compared to TLX's ROE of -0.02%. Regarding short-term risk, IRON is more volatile compared to TLX. This indicates higher risk in terms of short-term price fluctuations for IRON.Check TLX's competition here